

Top 10 Biologic Drugs by US Sales, 2012

Rank	Product	Company	US sales \$ (millions)	% change vs. prior year
1	Humira	Eli Lilly	\$4,608.5	23.1%
2	Enbrel	Amgen	\$4,336.6	15.1%
3	Remicade	J& J/Merck	\$3,876.1	11.1%
4	Copaxone	Teva	\$3,581.1	13.3%
5	Neulasta	Amgen	\$3,459.6	4.0%
6	Rituxan	Genentech/ Biogen Idec	\$3,196.7	7.5%
7	Avastin	Genentech	\$2,660.8	-0.1%
8	Lantus	Sanofi	\$2,326.3	12.5%
9	Lantus SoloStar	Sanofi	\$2,189.3	37.3%
10	Epogen	Amgen	\$2,166.8	-22.0%

Source: IMS Health, MIDAS, MAT Dec 2012, US Biologic market at trade level